The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines* *Preliminary results of this analysis were presented at the 9th annual HMO Research Network Conference April 1-2, 2003

Meltzer, 1997, The prevalence and medical and economic impact of allergic rhinitis in the United States, J Allergy Clin Immunol, 99, S805 United States Bureau of the Census, 2001 Ray, 1999, Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses, J Allergy Clin Immuno, 103, 401, 10.1016/S0091-6749(99)70463-X Crystal-Peters, 2000, The cost of productivity losses associated with allergic rhinitis, Am J Manag Care, 6, 373 Goetzel, 2000, Pharmaceuticals—cost or investment? An employer's perspective, J Occup Environ Med, 42, 338, 10.1097/00043764-200004000-00002 Teitelbaum, 2002 Emron, 2001 Saranow Gellene, 2002, WellPoint to favor nonprescription form of claritin, Los Angeles Times Roper Starch. Self-Care in the New Millennium. Consumer Healthcare Products Association. Appendix, p. 43. Finkle, 2002, Increased risk of serious injury following an initial prescription for diphenhydramine, Ann Allergy Asthma Immunol, 89, 244, 10.1016/S1081-1206(10)61950-3 Gaillard, 1988, The influence of antihistamines on human performance, Eur J Clin Pharmacol, 35, 249, 10.1007/BF00558261 Gilmore, 1996, Occupational injuries and medication use, Am J Ind Med, 30, 234, 10.1002/(SICI)1097-0274(199608)30:2<234::AID-AJIM16>3.0.CO;2-Y Cockburn, 1999, Loss of work productivity due to illness and medical treatment, J Occup Environ Med, 41, 948, 10.1097/00043764-199911000-00005 Adelsberg, 1997, Sedation and performance issues in the treatment of allergic conditions, Arch Intern Med, 157, 494, 10.1001/archinte.1997.00440260028006 Witek, 1995, Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists, Ann Allergy Asthma Immunol, 74, 419 Kay, 2001, Impact of sedating antihistamines on safety and productivity, Allergy Asthma Proc, 22, 281 Estelle, 1999, H1-receptor antagonists: safety issues, Ann Allergy Asthma Immunol, 83, 481, 10.1016/S1081-1206(10)62855-4 Vuurman, 1993, Seasonal allergic rhinitis and antihistamine effects on children's learning, Ann Allergy, 71, 121 American Academy of Allergy Asthma and Immunology, American College of Allergy Asthma and Immunology, Joint Council of Allergy Asthma and Immunology. Insurance Coverage for H1-Antihistamines: Implications for Quality Healthcare and Public Safety, 2002. Fairman, 2001 Sullivan, 2003, Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis, Med Care, 41, 1382, 10.1097/01.MLR.0000100584.18276.C4 Drug Store News New York Health Plan Association. Cost of Certain Antihistamines to New York's Insured Population, 2001. Belshe, 1998 Leibowitz, 1985, The demand for prescription drugs as a function of cost-sharing, Soc Sci Med, 21, 1063, 10.1016/0277-9536(85)90161-3 Keeler, 2002, The benefits of switching smoking cessation drugs to over-the-counter status, Health Econ, 11, 389, 10.1002/hec.677 Motheral, 1999, The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation, Am J Manag Care, 5, 1383 Dykewicz, 1998, Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology, Ann Allergy Asthma Immunol, 81, 478, 10.1016/S1081-1206(10)63155-9 Thomas, 1977, Double-blind, controlled study of clemastine fumarate, chlorpheniramine and placebo in patients with seasonal allergic rhinitis, Ann Allergy, 38, 169 Todd, 1975, Double-blind trials of clemastine (“Tavegil”) in allergic rhinitis, Curr Med Res Opin, 3, 126, 10.1185/03007997509113659 Sheriff, 1976, A comparative study of clemastine (“Tavegil”) and chlorpheniramine maleate in the treatment of hay fever, Curr Med Res Opin, 4, 245, 10.1185/03007997609109312 Harvey, 1996, Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis, J Allergy Clin Immunol, 97, 1233, 10.1016/S0091-6749(96)70190-2 Horak, 1988, A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis, Arzneimittelforschung, 38, 124 Del Carpio, 1989, Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis, J Allergy Clin Immunol, 84, 741, 10.1016/0091-6749(89)90303-5 Bruttmann, 1989, Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis, J Allergy Clin Immunol, 83, 411, 10.1016/0091-6749(89)90127-9 Day, 1997, Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis, Ann Allergy Asthma Immunol, 79, 163, 10.1016/S1081-1206(10)63104-3 Kemp, 1985, Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis, Ann Allergy, 54, 502 Dockhorn, 1987, Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis, Ann Allergy, 58, 407 Lockey, 1989, Loratadine (SCH 29851) 10 mg OD versus clemastine 1 mg BID in the treatment of perennial allergic rhinitis, Immunol Allergy Pract, 11, 10 Buckley, 1988, Terfenadine treatment of fall hay fever, Ann Allergy, 60, 123 American College of Allergy Asthma and Immunology, 2002 Druce, 1998, Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial, J Clin Pharmacol, 38, 382, 10.1002/j.1552-4604.1998.tb04439.x Alexander, 1994, Efficacy and tolerability of cetirizine, loratadine and placebo in the treatment of seasonal allergic rhinitis (SAR): a Canadian multicentre study (abstract), J Allergy Clin Immunol, 93, 163 Brandon, 1980, Clinical investigation of terfenadine, a non-sedating antihistamine, Ann Allergy, 44, 71 Melillo, 1982, A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis, Arzneimittelforschung, 32, 1202 Brostoff, 1982, Controlled trial of terfenadine and chlorpheniramine maleate in perennial rhinitis, Postgrad Med J, 58, 422, 10.1136/pgmj.58.681.422 Backhouse, 1982, Terfenadine in allergic rhinitis. A comparative trial of a new antihistamine versus chlorpheniramine and placebo, Practitioner, 226, 347 Weiler, 2000, Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator, Ann Intern Med, 132, 354, 10.7326/0003-4819-132-5-200003070-00004 O'Hanlon, 1995, Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94, Allergy, 50, 234, 10.1111/j.1398-9995.1995.tb01140.x Vinson, 1995, Alcohol and injury. A case-crossover study, Arch Fam Med, 4, 505, 10.1001/archfami.4.6.505 Simpson, 1985, Polydrug effects and traffic safety, J Alcohol Drugs Driving, 1, 17 National Highway Traffic Safety Administration, 2001 National Safety Council, 2000 Drugstore.com [Internet]. [Accessed 2002 Mar 18] Available from: http://www.drugstore.com. http://www.walgreens.com [Internet]. [Accessed 2003 May 8] Available from: http://www.walgreens.com. Managed Care Measures LLC. Respiratory Benchmarks, 2000. National Safety Council, 2001 Blincoe, 2002 1996 Gold, 1998, Toward consistency in cost-utility analyses: using national measures to create condition-specific values, Med Care, 36, 778, 10.1097/00005650-199806000-00002 Fryback, 1993, The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors, Med Decis Making, 13, 89, 10.1177/0272989X9301300202 Fryback, 2001, An elementary introduction to bayesian computing using WinBUGS, Int J Technol Assess, 17, 98, 10.1017/S0266462301104095 Briggs, 2000, Handling uncertainty in cost-effectiveness models, Pharmacoeconomics, 17, 479, 10.2165/00019053-200017050-00006 Briggs, 2002, Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease, Med Decis Making, 22, 290, 10.1177/027298902400448867 Cantor, 1994, Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment, Med Decis Making, 14, 259, 10.1177/0272989X9401400308 Stinnett, 1998, Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis, Med Decis Making, 18, S68, 10.1177/0272989X9801800209